[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100588659":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":10,"centralContacts":49,"locations":10,"responsibleParty":55,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":10,"eligibilityCriteria":66,"healthyVolunteers":63,"sex":67,"minAge":68,"maxAge":10,"enrollmentInfo":69,"targetDuration":72,"studyType":73,"phases":10,"briefSummary":74,"conditions":75,"keywords":10,"overallStatus":77,"whyStopped":10,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":10},{"fullName":5,"class":6},"Liverpool School of Tropical Medicine","OTHER",[8,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Non-haemorrhagic cases",null,"This cohort will include laboratory confirmed cases of haemorrhagic fever with renal syndrome without any evidence of haemorrhagic manifestations.",[13,14,15,16,17,18],"Procedure: Blood draw for thromboelastography - admission","Procedure: Blood draw for thromboelastography - follow-up","Procedure: Blood draw for transcriptomic analysis","Other: Data collection - clinical\u002Fdemographic\u002Fepidemiological data","Other: Data collection - routine laboratory parameters","Other: Severity score calculation",{"label":20,"type":10,"description":21,"interventionNames":22},"Haemorrhagic cases","This cohort will include laboratory confirmed cases of haemorrhagic fever with renal syndrome with evidence of haemorrhagic manifestations.",[13,14,15,16,17,18],[24,29,33,37,41,45],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"PROCEDURE","Blood draw for thromboelastography - admission","Two blood samples will be collected at admission for thromboelastography using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.",[20,9],{"type":25,"name":30,"description":31,"armGroupLabels":32,"otherNames":10},"Blood draw for thromboelastography - follow-up","Two blood samples will be collected 3 - 7 days after initial thromboelastography for follow-up analysis using the TEG 6s platform (Haemonetics®). One sample will be collected in a citrated blood tube for global haemostasis assessment, and one sample will be collected in a heparinised tube for platelet function analysis.",[20,9],{"type":25,"name":34,"description":35,"armGroupLabels":36,"otherNames":10},"Blood draw for transcriptomic analysis","One blood sample will be collected at admission for transcriptomic analysis. Blood sample will be collected into a PAXgene® RNA tube and analysed using nanopore sequencing to characterise the viral and host transcriptome.",[20,9],{"type":6,"name":38,"description":39,"armGroupLabels":40,"otherNames":10},"Data collection - clinical\u002Fdemographic\u002Fepidemiological data","Routine clinical\u002Fdemographic\u002Fepidemiological data will be collected at admission and throughout hospitalisation. This will relate to clinical presentation (day of illness at presentation, presenting symptoms); demographics and epidemiology (age, gender, site of infection); clinical course during hospitalisation (maximum level of care, dialysis use, blood product use, survival outcome).",[20,9],{"type":6,"name":42,"description":43,"armGroupLabels":44,"otherNames":10},"Data collection - routine laboratory parameters","Data on routine laboratory parameters will be collected throughout hospitalisation. These will relate to laboratory clotting parameters (platelet count, prothrombin time, activated partial thromboplastin time, fibrinogen, D-dimer); liver function tests (aspartate aminotransferase, alanine aminotransferase); laboratory haematology parameters (haemoglobin, white cell count, blood film); laboratory biochemistry parameters (urea, creatinine); viral load.",[20,9],{"type":6,"name":46,"description":47,"armGroupLabels":48,"otherNames":10},"Severity score calculation","A severity score will be assigned to each patient based on clinical and laboratory data at admission according to a pre-defined scoring system.",[20,9],[50],{"name":51,"role":52,"phone":53,"phoneExt":10,"email":54},"Matthew J Riley, MBChB, MRes, DTMH, MRCP(UK)","CONTACT","+44 7557407661","Matthew.Riley@lstmed.ac.uk",{"type":56,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[58],{"name":59,"class":60},"Institute of microbiology and immunology, Slovenia","UNKNOWN","100588659","characterising-the-loss-of-haemostasis-in-haemorrhagic-fever-with-renal-syndrome-100588659",false,"NCT06944275","Characterising the Loss of Haemostasis in Haemorrhagic Fever With Renal Syndrome","Inclusion Criteria:\n\n* Patients aged 18 or older, including pregnant women\n* Laboratory-confirmed HFRS (serology and\u002For RT-PCR)\n* Willing and able to provide informed consent\n\nExclusion Criteria:\n\n* Patients under 18 years of age\n* Co-infections with other pathogens\n* Pre-existing coagulation disorders\n* Use of anticoagulant medication\n* Inability or refusal to provide consent","ALL","18 Years",{"count":70,"type":71},62,"ESTIMATED","7 Days","OBSERVATIONAL","Hantaviruses are globally distributed viruses that cause haemorrhagic fever with renal syndrome (HFRS) in Europe, a disease characterised by acute kidney failure and, in some cases, significant bleeding complications. The mechanisms underlying clotting abnormalities in HFRS remain poorly understood. This study aims to investigate the pathological mechanisms of clotting dysfunction in hospitalised HFRS patients, assess the impact of different hantavirus types on disease severity, and evaluate the accuracy of a severity scoring system developed in China for predicting mortality in European patients.\n\nHospitalised patients with laboratory-confirmed HFRS will be prospectively recruited from University Medical Centre Ljubljana, Slovenia. Blood samples will be analysed for routine laboratory markers, thromboelastography (TEG) will assess real-time clotting function, and transcriptomic analysis will identify hantavirus strains and gene expression patterns linked to disease severity. Patients will be stratified into haemorrhagic and non-haemorrhagic groups, with statistical analyses comparing clinical and laboratory parameters to identify predictors of bleeding risk. Findings from this study may contribute to improved risk stratification and potential therapeutic targets for HFRS.",[76],"Haemorrhagic Fever With Renal Syndrome","NOT_YET_RECRUITING","2025-11-18",{"date":80,"type":81},"2025-11-19","ACTUAL",{"date":83,"type":71},"2026-05-01",{"date":85,"type":71},"2027-08-31",{"name":5,"class":6}]